Anebulo Pharmaceuticals Inc. reported its financial results for the third quarter of fiscal year 2025, ending on March 31, 2025. The pharmaceutical company recorded operating expenses of $1.9 million, an increase from the $1.7 million reported in the same period of fiscal 2024. The net loss remained steady at $1.7 million for the third quarter of fiscal 2025, matching the net loss recorded in the same quarter of the previous fiscal year. The company reported cash and cash equivalents amounting to $13.3 million as of March 31, 2025, and highlighted an additional $3 million available through a Loan Agreement. Anebulo Pharmaceuticals is focusing on advancing intravenous selonabant as a potential treatment for pediatric patients experiencing cannabis-induced Central Nervous System depression. The company plans to commence dosing healthy adult volunteers in a Phase 1 single ascending dose study of intravenous selonabant in the third quarter of calendar 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.